Suzhou Ribo Life Science Co., Ltd.
π¨π³China
- Country
- π¨π³China
- Ownership
- Holding
- Established
- 2007-01-18
- Employees
- 51
- Market Cap
- -
- Website
- http://www.ribolia.com
Clinical Trials
8
Active:2
Completed:4
Trial Phases
3 Phases
Phase 1:6
Phase 2:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Phase 1
6 (75.0%)Not Applicable
1 (12.5%)Phase 2
1 (12.5%)Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy Participants
Not Applicable
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- Drug: RBD1119Drug: Placebo
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT07042594
- Locations
- π¦πΊ
CMAX Clinical Research, Adelaide, Australia
A Study of RBD1016 in CHB Participants
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05961098
- Locations
- π¨π³
Prince of Wales Hospital, Hong Kong, China
π¨π³Queen Mary Hospital, Hong Kong, China
πΈπͺKarolinska University Hospital, Stockholm, Sweden
A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05912296
- Locations
- π¨π³
Peking Union Medical College Hospital, Beijing, Beijing, China
A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05653037
- Locations
- π¦πΊ
Q-Pharm Pty Limited, Brisbane, Australia
A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Suzhou Ribo Life Science Co. Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT05539651
- Locations
- π¦πΊ
Q-Pharm Pty Limited, Brisbane, Australia
- Prev
- 1
- 2
- Next
News
No news found